We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in our Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Lung Cancer

Journal Scan / Research · August 30, 2022

Final Analysis of Alectinib vs Crizotinib in ALK Inhibitor–Naïve Japanese Patients With ALK-Positive NSCLC



Additional Info

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer
ESMO Open 2022 Jul 14;7(4)100527, K Hotta, T Hida, H Nokihara, M Morise, YH Kim, K Azuma, T Seto, Y Takiguchi, M Nishio, H Yoshioka, T Kumagai, S Watanabe, K Goto, M Satouchi, T Kozuki, T Shukuya, K Nakagawa, T Mitsudomi, N Yamamoto, T Asakawa, T Yoshimoto, S Takata, T Tamura

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading